Handelsbanken Fonder’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-17,651
| Closed | -$2.26M | – | 1504 |
|
|
2025
Q2 | $2.26M | Sell |
17,651
-1,000
| -5% | -$104K | 0.01% | 618 |
|
|
2025
Q1 | $1.65M | Hold |
18,651
| – | – | 0.01% | 725 |
|
|
2024
Q4 | $1.63M | Buy |
18,651
+3,000
| +19% | +$275K | 0.01% | 754 |
|
|
2024
Q3 | $1.45M | Hold |
15,651
| – | – | 0.01% | 785 |
|
|
2024
Q2 | $1.69M | Buy |
15,651
+2,500
| +19% | +$250K | 0.01% | 627 |
|
|
2024
Q1 | $1.25M | Hold |
13,151
| – | – | 0.01% | 758 |
|
|
2023
Q4 | $1.21M | Hold |
13,151
| – | – | 0.01% | 719 |
|
|
2023
Q3 | $660K | Hold |
13,151
| – | – | ﹤0.01% | 920 |
|
|
2023
Q2 | $831K | Sell |
13,151
-1,700
| -11% | -$92.4K | ﹤0.01% | 818 |
|
|
2023
Q1 | $668K | Buy |
14,851
+4,600
| +45% | +$207K | ﹤0.01% | 861 |
|
|
2022
Q4 | $449K | Buy |
10,251
+700
| +7% | +$33.6K | ﹤0.01% | 1017 |
|
|
2022
Q3 | $629K | Hold |
9,551
| – | – | ﹤0.01% | 842 |
|
|
2022
Q2 | $482K | Hold |
9,551
| – | – | ﹤0.01% | 1042 |
|
|
2022
Q1 | $610K | Hold |
9,551
| – | – | ﹤0.01% | 1064 |
|
|
2021
Q4 | $1.02M | Sell |
9,551
-2,500
| -21% | -$262K | 0.01% | 875 |
|
|
2021
Q3 | $1.24M | Hold |
12,051
| – | – | 0.01% | 792 |
|
|
2021
Q2 | $1.06M | Buy |
12,051
+3,000
| +33% | +$275K | 0.01% | 887 |
|
|
2021
Q1 | $880K | Hold |
9,051
| – | – | 0.01% | 899 |
|
|
2020
Q4 | $1.01M | Hold |
9,051
| – | – | 0.01% | 823 |
|
|
2020
Q3 | $839K | Hold |
9,051
| – | – | 0.01% | 782 |
|
|
2020
Q2 | $706K | Buy |
+9,051
| New | +$612K | 0.01% | 806 |
|
|
2018
Q4 | – | Sell |
-19,000
| Closed | -$1.48M | – | 172 |
|
|
2018
Q3 | $1.48M | Hold |
19,000
| – | – | 0.03% | 167 |
|
|
2018
Q2 | $1.21M | Buy |
+19,000
| New | +$1.51M | 0.02% | 178 |
|
Other funds holding BPMC
IA
HNB
Handelsbanken Fonder's BPMC Position: Q3 2025 in Review
Handelsbanken Fonder sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 17,651 shares — an estimated $2.26M sold.
Handelsbanken Fonder first reported a position in BPMC in Q2 2018 and held it in 23 quarters. The position peaked at $2.26M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Handelsbanken Fonder reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Handelsbanken Fonder sold 17,651 Blueprint Medicines shares in Q3 2025, an estimated $2.26M.
- Handelsbanken Fonder first reported a position in Blueprint Medicines in Q2 2018 and held it in 23 quarters.
- Handelsbanken Fonder's Blueprint Medicines position peaked at $2.26M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Handelsbanken Fonder's 13F filing for Q3 2025, filed 12 Nov 2025.